How Mark Cuban is Turning the Prescription Drug Industry Upside Down

When Mark Cuban enters an industry, he typically disrupts it in one way or another. And that’s precisely what it appears he has done once again, though this time in the healthcare space. His Cost Plus Drug Company has turned the industry on its head and introduced transparency to the previously opaque area of prescription drug prices.

“We started [Mark Cuban Cost Plus Drug Company] with the goal of being the low-cost provider for generic drugs,” Cuban told MarketScale. 

The company’s website features a chart displaying the stark difference in the retail price of these drugs versus what consumers pay through their platform. But perhaps the most striking thing about the Cost Plus Drug Company is the clarity of the pricing structure. Leadership has been vocal, on the site and on social media, about how Cost Plus Drugs gets to its final prices in an effort to set a new standard for patient-focused transparency.

For example, every drug is priced with the same markups: a 15% markup supports operations, a $3 charge covers pharmacy labor, and then the usual fixed and variable costs of shipping round out the total. Some savings are minimal; a 60-count of 20mg Fluoxetine, the generic alternative for depression and OCD treatment drug Prozac, costs $4.80 for a Cost Plus Drugs customer, compared to the retail price of $43.80.

Some savings are so stark that they warrant a double take. For a 30-count of 400mg Imatinib, the generic version of leukemia-treatment drug Gleevec, Cost Plus Drugs customers pay $47.50, compared to the retail price of $9,657.40, an enormous difference in cost.

“We will do whatever it takes to get affordable pharmaceuticals to patients,” said Alex Oshmyansky, CEO of Mark Cuban Cost Plus Drug. “The markup on potentially lifesaving drugs that people depend on is a problem that can’t be ignored. It is imperative that we take action and help expand access to these medications for those who need them most.”

With this cost savings business model, underinsured or uninsured patients who’d be paying close to or full price would see the most immediate benefits. Even insured patients though, according to the company’s site, would pay “less than what you would pay when using your insurance at a typical pharmacy.”

The cost of drugs in the United States has been a problem for some time, garnering attention from President Biden and putting a financial strain on many Americans. According to Kevin Stevenson, Director of Strategic Operations at Providence Healthcare Network in Waco, TX, affecting positive change in this side of the industry is critical, as for patients, it’s truly a life or death situation.

“People who don’t have insurance that are paying out of pocket, oftentimes they skip medications because they take food out of their family’s mouth,” Stevenson said.

The high-profile attention that Cuban’s company, as well as the issue at-large, is getting could be a sign of things to come for healthcare in the United States.

“I think we’re seeing people in healthcare now that are having that more entrepreneurial mindset, that are looking at problems and saying how can we look at it from a different viewpoint to try to solve this,” he said.

Stevenson admitted that change in healthcare can come slowly, but with sharks like Mark Cuban in the water, change could be coming sooner rather than later. 

Follow us on social media for the latest updates in B2B!

Image

Latest

influencer partnerships
Moving Beyond Social Media Buzz: How Authentic Content & Long-Term Influencer Partnerships Can Drive Hotel ROI
July 30, 2025

Influencer marketing is rapidly changing, and many hotels are still figuring out how to tap into its full potential. As travelers demand more authentic and relatable content, the pressure is on for hotels to adapt their marketing strategies. But with skepticism around the true ROI of influencer partnerships, it’s more important than ever for brands…

Read More
workforce
Building a Future-Ready Workforce: With Traditional Training Models Failing, It’s Time for Employers and Educators to Build Solutions Together
July 30, 2025

In an era where the average job tenure in the U.S. hovers under four years and industries are evolving faster than academic curricula can keep up, the need for a new approach to workforce development has never been more urgent. Companies like Amazon and McDonald’s are responding by investing in “education as a benefit”…

Read More
belief
Learning Out Loud with Belief, Courage, and the Power of Yes
July 30, 2025

In a world where workplace disengagement is on the rise, with global employee engagement falling to just 21% in 2024, leaders and teams are increasingly seeking meaning, connection, and growth in their work. Amid this shift, professionals are asking deeper questions about purpose and fulfillment, both individually and collectively. That’s exactly where Paul Plamondon’s…

Read More
professional advancement
The Measured Mindset: How Mentorship, Curiosity, and Listening Drive Professional Advancement and Growth
July 29, 2025

Not every path into analytics starts with code and spreadsheets. For some, it begins with curiosity, adaptability, mentorship, and a willingness to learn something entirely new. That’s the case for Mayank Malviya, whose journey from a humanities education in India to a career in U.S.-based market research reveals how initiative and mentorship can accelerate…

Read More